NiTech Solutions secures funding

Published: 1-Jun-2005


NiTech Solutions, a Scottish developer and manufacturer of innovative reactor systems for the chemical and pharmaceutical industries, has secured new funding package of £750,000, comprised of awards from a variety of sources, including:

• a second SMART-Scotland award;

• regional Selective Assistance (RSA);

• private investors;

• Scottish Enterprise's Business Growth and Scottish Co-Investment Funds;

• Bank of Scotland Small Firms Loan Guarantee Fund (SFLGF).

It will be used to obtain and fit out premises, assist with recruitment of staff, invest in the plant and equipment to demonstrate further applications, increase sales and marketing activity, and further develop and protect intellectual property.

Its key product is an oscillatory baffled reactor that uses innovative mixing technology and is applicable to a wide range of pharmaceutical processes.

  • Companies:
  • Nitech Solutions
See more

You may also like

Manufacturing

NiTech Solutions chooses Nalas Engineering for a partnership in the US

Read more
The maker of continuous oscillating baffle reactors has joined forces with the chemistry and chemical company based in Centerbrook, Connecticut

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

NiTech Solutions chooses Nalas Engineering for a partnership in the US

The maker of continuous oscillating baffle reactors has joined forces with the chemistry and chemical company based in Centerbrook, Connecticut

Plug flow: fact and myth

<p>Plug flow offers many benefits in reaction chemistry but, as yet, is not widely used. Professor Xiong-Wei Ni, of NiTech Solutions, outlines the principles, advantages and limitations</p>
Manufacturing

For easy transition from glass to plastic accessories - BOLA components with GL threads

The GL thread is the most common thread on lab equipment made of glass. Available from Labtex in the UK, BOLA offers a modular construction system with many different components with GL threads
Distribution

ChargePoint invest in a single-use manufacturing facility to expand product line

The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Research & Development

Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool

The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Manufacturing

Optimising RNA production for faster and cheaper pharmaceutical manufacturing

RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the avoidance of scaling issues
Research & Development

New automated tissue dissociation systems

Introducing the new Singulator series (100 and 200)
Subscribe now